Marshall Wace’s Annovis Bio ANVS Stock Holding History

Marshall Wace’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.65M	Buy	1,187,499 +461,637	+64%	+$1.27M	﹤0.01%	1627
2025 Q4	$2.51M	Buy	+725,862	New	+$2.18M	﹤0.01%	1465
2025 Q3	–	Sell	-90,907	Closed	-$197K	–	2865
2025 Q2	$197K	Buy	+90,907	New	+$179K	﹤0.01%	2459
2024 Q1	–	Sell	-32,582	Closed	-$609K	–	2410
2023 Q4	$609K	Buy	+32,582	New	+$289K	﹤0.01%	1642
2022 Q1	–	Sell	-1,679	Closed	-$29K	–	3311
2021 Q4	$29K	Buy	+1,679	New	+$43.3K	﹤0.01%	3662

Other funds holding ANVS

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's ANVS Position: Q1 2026 in Review

Marshall Wace increased its Annovis Bio (ANVS) stake by 64% in Q1 2026, buying an estimated $1.27M and bringing the position to 1,187,499 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Marshall Wace first reported a position in ANVS in Q4 2021 and has held it in 5 quarters since. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

Marshall Wace held 1,187,499 shares of Annovis Bio worth $2.65M as of Q1 2026.
Marshall Wace bought 461,637 Annovis Bio shares in Q1 2026, an estimated $1.27M.
Annovis Bio made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1627 holding.
Marshall Wace first reported a position in Annovis Bio in Q4 2021 and has held it in 5 quarters since.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.